Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities.

Maher L, White B, Hellard M, Madden A, Prins M, Kerr T, Page K.

Vaccine. 2010 Oct 21;28(45):7273-8. doi: 10.1016/j.vaccine.2010.08.085. Epub 2010 Sep 9. Review.

2.

Hepatitis C virus vaccines among people who inject drugs.

Cox AL, Thomas DL.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S46-50. doi: 10.1093/cid/cit329. Review.

3.

Assessing the feasibility of hepatitis C virus vaccine trials: results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study.

White B, Madden A, Prins M, Hellard M, Wand H, Dore GJ, Page K, Maher L.

Vaccine. 2014 Sep 22;32(42):5460-7. doi: 10.1016/j.vaccine.2014.07.091. Epub 2014 Aug 12.

4.

Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials: perspectives of people who inject drugs.

Park JN, White B, Bates A, Enriquez J, Liao L, Maher L.

Drug Alcohol Depend. 2012 Jun 1;123(1-3):35-40. doi: 10.1016/j.drugalcdep.2011.10.009. Epub 2011 Nov 8.

PMID:
22071117
5.

"Fitness for duty": social, organisational and structural influences on the design and conduct of candidate hepatitis C vaccine trials involving people who inject drugs.

Treloar C, Byron P, McCann P, Maher L.

Vaccine. 2010 Jul 19;28(32):5228-36. doi: 10.1016/j.vaccine.2010.05.064. Epub 2010 Jun 9.

PMID:
20538093
6.

WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs.

Walsh N, Verster A, Rodolph M, Akl EA.

Int J Drug Policy. 2014 May;25(3):363-71. doi: 10.1016/j.drugpo.2014.01.009. Epub 2014 Jan 26.

PMID:
24561223
7.

Hepatitis C vaccine clinical trials among people who use drugs: potential for participation and involvement in recruitment.

Young AM, Stephens DB, Khaleel HA, Havens JR.

Contemp Clin Trials. 2015 Mar;41:9-16. doi: 10.1016/j.cct.2014.12.015. Epub 2014 Dec 30.

8.

Increased hepatitis C virus vaccine clinical trial literacy following a brief intervention among people who inject drugs.

White B, Madden A, Hellard M, Kerr T, Prins M, Page K, Dore GJ, Maher L.

Drug Alcohol Rev. 2013 Jul;32(4):419-25. doi: 10.1111/dar.12000. Epub 2012 Nov 1.

9.

Novel interventions to prevent HIV and HCV among persons who inject drugs.

Coffin PO, Rowe C, Santos GM.

Curr HIV/AIDS Rep. 2015 Mar;12(1):145-63. doi: 10.1007/s11904-014-0248-2. Review.

PMID:
25589380
10.

Are young injection drug users ready and willing to participate in preventive HCV vaccine trials?

Levy V, Evans JL, Stein ES, Davidson PJ, Lum PJ, Hahn JA, Page K.

Vaccine. 2010 Aug 23;28(37):5947-51. doi: 10.1016/j.vaccine.2010.07.006. Epub 2010 Jul 16.

11.

Ethical issues in HIV prevention research with people who inject drugs.

Sugarman J, Rose SM, Metzger D.

Clin Trials. 2014 Apr;11(2):239-45. doi: 10.1177/1740774513505157. Epub 2013 Oct 14.

12.

Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review.

Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Dhersin JS, Yazdanpanah Y.

J Viral Hepat. 2015 Mar;22(3):213-29. doi: 10.1111/jvh.12337. Epub 2014 Oct 1. Review.

13.

Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.

Bruggmann P, Grebely J.

Int J Drug Policy. 2015 Feb;26 Suppl 1:S22-6. doi: 10.1016/j.drugpo.2014.08.014. Epub 2014 Aug 30.

14.

Can hepatitis C virus infection be eradicated in people who inject drugs?

Grebely J, Dore GJ.

Antiviral Res. 2014 Apr;104:62-72. doi: 10.1016/j.antiviral.2014.01.002. Epub 2014 Jan 24. Review.

PMID:
24468275
15.

Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.

MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, Taylor A, Roy K, Aspinall E, Goldberg D, Rhodes T, Hedrich D, Salminen M, Hickman M, Hutchinson SJ.

Int J Drug Policy. 2014 Jan;25(1):34-52. doi: 10.1016/j.drugpo.2013.07.001. Epub 2013 Aug 21. Review.

PMID:
23973009
16.

An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011.

Bowring AL, Luhmann N, Pont S, Debaulieu C, Derozier S, Asouab F, Toufik A, van Gemert C, Dietze P, Stoove M.

Int J Drug Policy. 2013 Jan;24(1):78-81. doi: 10.1016/j.drugpo.2012.08.005. Epub 2012 Oct 1.

PMID:
23036650
17.

Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.

Grebely J, Matthews GV, Lloyd AR, Dore GJ.

Clin Infect Dis. 2013 Oct;57(7):1014-20. doi: 10.1093/cid/cit377. Epub 2013 May 31.

PMID:
23728143
18.

Using ethnographic fieldwork to inform hepatitis C vaccine preparedness studies with people who inject drugs.

Maher L, White B, Donald A, Bates A, Enriquez J, Pham S, Liao L.

Int J Drug Policy. 2010 May;21(3):194-201. doi: 10.1016/j.drugpo.2009.04.004. Epub 2009 May 30.

PMID:
19482463
19.

Global policy and access to new hepatitis C therapies for people who inject drugs.

Doyle JS, Aspinall EJ, Hutchinson SJ, Quinn B, Gore C, Wiktor SZ, Hellard ME.

Int J Drug Policy. 2015 Nov;26(11):1064-71. doi: 10.1016/j.drugpo.2015.05.008. Epub 2015 Jun 2. Review.

PMID:
26118794
20.

Populations who test drugs should benefit from them.

Basu S, Andrews J, Smith-Rohrberg D.

Nature. 2006 Mar 30;440(7084):605. No abstract available.

PMID:
16572144

Supplemental Content

Support Center